Telehealth companies are promoting GLP-1 medications such as Ozempic and Wegovy for cosmetic weight loss in non-obese patients, despite FDA limitations on their approved use, according to a Nov. 24 ...

Weight-loss drugs are coming for a new kind of customer. “You don’t need to be obese to start a GLP-1,” reads an ad from a telehealth startup, the words scrawled in icing on a cake. Another one ...

As competitive as the obesity drug market has become, Novo Nordisk's decision to slash the prices of its GLP-1 agonist drugs ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

The recent stock weakness has a clear and powerful trigger. Novo Nordisk has dramatically slashed prices for its blockbuster drugs, Wegovy and Ozempic. The monthly cost for patients will drop from ...

Investors delivered a harsh verdict on Hims & Hers Health's latest financial results, driving shares down sharply despite what appeared to be strong oper ...

Shares of Hims & Hers are trading marginally lower Monday morning, as competitive news overshadows bullish announcements from ...

Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, ...

Investing.com -- Hims & Hers Health, Inc. (NYSE:HIMS) stock rose 1.5% on Monday after the health and wellness platform announced a new $250 million share repurchase program. The authorization comes ...

Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness ...

Novo Nordisk cuts obesity drug prices to compete with Eli Lilly, offering new patient deals and nationwide access.